Net income decreased 18.7%
Net income changed -18.7% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Net income changed -18.7% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Capital expenditure changed +154.7% from the comparable as-filed period.
Gross margin changed -71 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Current assets changed -13.8% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Operating cash flow changed +8.7% from the comparable as-filed period.
Operating cash flow / net income changed +33.8% from the comparable as-filed period.
Capex / revenue changed +108 basis points from the comparable as-filed period.
Free-cash-flow proxy changed +4.9% from the comparable as-filed period.
Revenue changed +0.8% from the comparable as-filed period.
Operating cash-flow margin changed +216 basis points from the comparable as-filed period.
Current ratio changed -15.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Current liabilities changed +2.2% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Receivables / revenue changed +60 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Free-cash-flow margin changed +108 basis points from the comparable as-filed period.
Gross profit changed -0.0% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
R&D / revenue changed -21 basis points from the comparable as-filed period.
Trade receivables changed +1.9% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Research & development changed +0.0% from the comparable as-filed period.
Cost of revenue changed +5.5% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.